Anzeige
Mehr »
Dienstag, 12.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14156 | ISIN: GB00BYMT0J19 | Ticker-Symbol: LIA
Tradegate
12.05.26 | 17:13
60,00 Euro
0,00 % 0,00
1-Jahres-Chart
LIVANOVA PLC Chart 1 Jahr
5-Tage-Chart
LIVANOVA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
61,0061,5023:01
61,0061,5021:59

Aktuelle News zur LIVANOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLivaNova forecasts 7%-8% 2026 revenue growth while outlining $4.20-$4.30 EPS2
LIVANOVA Aktie jetzt für 0€ handeln
MiLivaNova PLC - 10-Q, Quarterly Report2
MiLivaNova übertrifft Q1-Prognosen 2026: Aktie legt deutlich zu2
MiLivaNova Q1 2026 Earnings Call Transcript1
MiLivaNova übertrifft Erwartungen, doch verhaltener Ausblick belastet die Aktie1
MiLivaNova PLC Non-GAAP EPS of $0.98 beats by $0.08, revenue of $362.3M beats by $16.19M2
MiLivaNova PLC: LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance436Delivered double-digit reported and constant-currency revenue growth Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) Received U.S. Food and Drug Administration...
► Artikel lesen
MiLivaNova PLC - 8-K, Current Report2
21.04.LivaNova reports positive findings for sleep apnea neuromod1
20.04.LivaNova PLC: Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea383Study demonstrates proximal hypoglossal nerve stimulation (pHGNS) yielded clinically significant responses and sustained improvements over time First rigorous RCT study design in HGNS space supports...
► Artikel lesen
25.03.LivaNova PLC: LivaNova to Announce First-Quarter 2026 Results293LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m....
► Artikel lesen
19.03.LivaNova gains FDA premarket approval for aura6000 for sleep apnea2
19.03.LivaNova wins FDA premarket approval for neuromod for sleep apnea1
19.03.LivaNova wins FDA approval for sleep apnea nerve device3
19.03.LivaNova PLC: LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea372First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language Next-generation, MRI-compatible device expected...
► Artikel lesen
26.02.Livanova: Wolfe Research erhöht Kursziel aufgrund positiver Epilepsie-Aussichten3
26.02.Wolfe Research raises Livanova stock price target on epilepsy outlook2
25.02.5 Analysts Assess LivaNova: What You Need To Know1
25.02.Stifel raises Livanova stock price target to $80 on strong growth1
25.02.LivaNova PLC - 10-K, Annual Report2
Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1